» Articles » PMID: 29112016

B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients

Overview
Date 2017 Nov 8
PMID 29112016
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Isolated MYC rearrangement without other recurrent genetic abnormalities is rare in B lymphoblastic leukemia/lymphoma (B-ALL/LBL), with most cases reported in pediatric patients. We report 3 adult cases with lymphoblasts showing a precursor B cell immunophenotype, and isolated MYC/IGH translocation. All 3 cases occurred in male patients with initial presentation of diffuse lymphadenopathy. Cases 1 and 2 had B-ALL with significantly increased lymphoblasts in peripheral blood and bone marrow. Case 3, a patient with human immunodeficiency virus infection, had the diagnosis of B-LBL made on a retroperitoneal lymph node biopsy and had no peripheral blood or bone marrow involvement. The leukemic and lymphoma cells in all 3 cases demonstrated Burkitt lymphoma-like morphology with deeply basophilic cytoplasm and numerous cytoplasmic vacuoles. However, all 3 had immature immunophenotypes including expression of terminal deoxynucleotidyl transferase (TdT), absence of BCL6, and dim-to-negative CD45. CD20 was largely negative in 2 of 3 cases. All 3 had confirmed MYC/IGH translocation, but lacked rearrangements of BCL2 or BCL6. EBV was negative by Epstein-Barr virus encoded small RNA in situ hybridization. Treatment protocols varied, including both high-risk ALL-type (protocol 8707) and high-grade lymphoma regimens (hyper-CVAD [cyclophosphamide, vincristine, adriamycin, and dexamethasone]), but no patient achieved continuous complete remission. These cases seem to represent a distinct biological phenomenon, in which a MYC translocation may be acquired at an immature stage of differentiation, thus manifesting features of both B-ALL/LBL and Burkitt lymphoma.

Citing Articles

B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination.

Schichman S, Penton A, Ghanta S, Konda M, Papenhausen P J Hematop. 2024; 16(2):111-117.

PMID: 38175445 PMC: 10766798. DOI: 10.1007/s12308-023-00541-y.


Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.

Quintanilla-Martinez L, Laurent C, Soma L, Ng S, Climent F, Ondrejka S Virchows Arch. 2023; 483(3):281-298.

PMID: 37555980 PMC: 10541818. DOI: 10.1007/s00428-023-03590-x.


Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia.

Pillsbury C, Dougan J, Rabe J, Fonseca J, Zhou C, Evans A Cancer Res Commun. 2023; 3(7):1248-1259.

PMID: 37465593 PMC: 10351425. DOI: 10.1158/2767-9764.CRC-23-0056.


Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2-myeloproliferative neoplasm.

Fukutsuka K, Iioka F, Maekawa F, Nakagawa M, Kishimori C, Hayashida M J Clin Exp Hematop. 2021; 61(2):114-119.

PMID: 33994432 PMC: 8265492. DOI: 10.3960/jslrt.21001.


Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.

Bouroumeau A, Kaphan E, Legrand C, Raskovalova T, Szymanski G, Vettier C J Med Case Rep. 2020; 14(1):117.

PMID: 32713346 PMC: 7384216. DOI: 10.1186/s13256-020-02433-6.


References
1.
Cai Q, Medeiros L, Xu X, Young K . MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015; 6(36):38591-616. PMC: 4770723. DOI: 10.18632/oncotarget.5774. View

2.
de Jong D, Voetdijk B, Beverstock G, van Ommen G, Willemze R, Kluin P . Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988; 318(21):1373-8. DOI: 10.1056/NEJM198805263182106. View

3.
Jabbour E, OBrien S, Konopleva M, Kantarjian H . New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015; 121(15):2517-28. PMC: 11726371. DOI: 10.1002/cncr.29383. View

4.
Imamura N, Mtasiwa D, Ota H, Inada T, Kuramoto A . FAB L3 type of B-cell acute lymphoblastic leukemia (B-ALL) without chromosome abnormalities. Am J Hematol. 1990; 35(3):216-8. DOI: 10.1002/ajh.2830350316. View

5.
Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View